Company Overview - Doximity is the largest online network for medical clinicians in the US, with 80% of US physicians and 50% of nurse practitioners and physician assistants as verified members [2] - The platform facilitates communication among healthcare professionals and allows for secure patient interactions via video calls, enhancing collaboration and information dissemination [3] Recent Developments - Doximity acquired Pathway Medical for $36 million, a Canadian company specializing in medical AI and clinical reference systems, which will enhance Doximity's offerings [8] - In fiscal 1Q26, Doximity reported revenue of $145.9 million, a 15% year-over-year increase, exceeding estimates by $6.36 million [9] Financial Performance - The company achieved a non-GAAP EPS of 36 cents, up from 28 cents year-over-year, and reported a 52% increase in free cash flow to $60.1 million [9] - Analysts expect Doximity's revenue growth to potentially accelerate in CY26, with a three-year revenue/EBITDA CAGR forecasted at 11%/12% [10] Analyst Ratings - Bank of America analyst Allen Lutz maintains a Buy rating on Doximity, with a price target of $82, suggesting a potential gain of approximately 24.5% [11] - The overall consensus rating for Doximity shares is Moderate Buy, based on 17 reviews, including 10 Buy, 5 Hold, and 2 Sell [11]

Core Viewpoint - Doximity (DOCS) is positioned to potentially continue its earnings-beat streak, having shown a strong history of exceeding earnings estimates, particularly in the last two quarters with an average surprise of 28.43% [1][5]. Earnings Performance - In the last reported quarter, Doximity achieved earnings of $0.36 per share, surpassing the Zacks Consensus Estimate of $0.31 per share, resulting in a surprise of 16.13% [2]. - In the previous quarter, the company was expected to report earnings of $0.27 per share but delivered $0.38 per share, leading to a surprise of 40.74% [2]. Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Doximity, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat, especially given its solid Zacks Rank [5][8]. - The current Earnings ESP for Doximity is +1.32%, suggesting that analysts are optimistic about its near-term earnings potential [8]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7]. Upcoming Earnings Report - Doximity's next earnings report is anticipated to be released on November 6, 2025, which could further clarify its earnings trajectory [8].

Industry Overview - Health and fitness companies are experiencing consistent demand due to increasing global awareness of health issues and the significance of physical fitness, driven by rising lifestyle-related diseases and a focus on preventive healthcare [1][10] - The industry's growth is supported by diverse revenue streams, including subscriptions, product sales, and services, making it appealing to long-term investors [2] Company Highlights Doximity Inc. (DOCS) - Doximity is a cloud-based digital platform for medical professionals in the U.S., covering over 80% of U.S. doctors and 60% of advanced practitioners, with a 95% subscription-based revenue model [7] - The company is expanding in a total addressable market of $18.55 billion and has integrated generative AI, enhancing product stickiness and physician utility [8] - Doximity's AI tools have seen a 5x usage growth year-over-year, supporting physicians in managing clinical documentation [9] - Expected revenue and earnings growth rates are 11.2% and 7%, respectively, for the current year [11] Planet Fitness Inc. (PLNT) - Planet Fitness is a leading franchisor and operator of fitness centers in the U.S., benefiting from higher royalties, new club openings, and member acquisitions [12] - The company ended Q2 with approximately 20.8 million members and over 2,762 clubs, achieving an 8.2% year-over-year increase in same-club sales [13] - Expected revenue and earnings growth rates are 10.2% and 13.1%, respectively, for the current year [14] United Natural Foods Inc. (UNFI) - United Natural Foods has shown strong growth supported by wholesale momentum and demand for natural and organic products, with strategic initiatives driving efficiency and cost savings [15][16] - The company has an expected revenue growth rate of 2.5% and earnings growth rate of over 100% for the current year [17] Peloton Interactive Inc. (PTON) - Peloton is evolving from a connected fitness brand to a broader wellness platform, leveraging commercial partnerships to drive growth [18] - The company has seen momentum in its Peloton for Business segment, with partnerships enhancing brand visibility [19] - Expected revenue and earnings growth rates are -1.1% and over 100%, respectively, for the current year [21] Performance Food Group Co. (PFGC) - Performance Food Group markets and distributes a wide range of food products, serving various sectors including restaurants and healthcare facilities [23][24] - The company has an expected revenue growth rate of 6.4% and earnings growth rate of 11.2% for the current year [25]

Company Performance - Doximity (DOCS) closed at $68.50, marking a +2.48% move from the prior day, outperforming the S&P 500 which gained 1.23% [1] - The stock has dropped by 10.16% in the past month, underperforming the Medical sector's gain of 4.41% and the S&P 500's gain of 2.45% [1] Upcoming Earnings - Doximity's earnings report is set to be released on November 6, 2025, with projected EPS of $0.38, indicating a 26.67% increase year-over-year [2] - Revenue is expected to be $157.79 million, reflecting a 15.32% increase compared to the same quarter last year [2] Full Year Estimates - For the full year, earnings are projected at $1.52 per share and revenue at $633.98 million, showing changes of +7.04% and +11.15% respectively from the previous year [3] - Recent revisions in analyst estimates suggest confidence in Doximity's business performance and profit potential [3] Zacks Rank and Valuation - Doximity currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook based on estimate revisions [5] - The company is trading at a Forward P/E ratio of 44.12, which is above the industry average of 40.8, suggesting a premium valuation [6] - Doximity has a PEG ratio of 3.21, compared to the industry average PEG ratio of 3.3 [6] Industry Context - The Medical Info Systems industry, part of the Medical sector, has a Zacks Industry Rank of 55, placing it in the top 23% of over 250 industries [7] - The top 50% rated industries outperform the bottom half by a factor of 2 to 1, indicating a strong industry performance [7]

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by officers and directors of Doximity Inc. (NYSE: DOCS), urging shareholders to contact the firm to discuss their rights and possible legal actions [1][2]. Summary by Relevant Sections Shareholder Rights - Shareholders who acquired Doximity stock on or before June 24, 2021, may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2]. Importance of Participation - Shareholder involvement is crucial for improving company policies and practices, enhancing transparency, accountability, and overall shareholder value [3]. Legal Representation - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors [4].

Core Insights - Doximity's stock closed at $65.61, down 9.59% from the previous session, underperforming compared to the S&P 500's loss of 2.71% [1] - The stock has increased by 3.29% over the past month, outperforming the Medical sector's gain of 2.6% but lagging behind the S&P 500's gain of 3.5% [1] Earnings Performance - Doximity is expected to report earnings of $0.38 per share, reflecting a year-over-year growth of 26.67% [2] - The consensus estimate for revenue is $157.73 million, indicating a 15.27% increase from the same quarter last year [2] - For the full year, analysts project earnings of $1.51 per share and revenue of $632.56 million, representing changes of +6.34% and +10.9% respectively from the previous year [3] Analyst Estimates - Recent changes in analyst estimates for Doximity are crucial as they reflect short-term business trends [4] - Positive estimate revisions are seen as a sign of optimism regarding the business outlook [4] Valuation Metrics - Doximity has a Forward P/E ratio of 48.18, which is higher than the industry average of 41.88 [7] - The company has a PEG ratio of 3.5, compared to the industry average PEG ratio of 3.32 [7] Industry Context - The Medical Info Systems industry, which includes Doximity, ranks in the bottom 41% of all industries according to the Zacks Industry Rank [8] - The Zacks Industry Rank indicates that the top 50% of rated industries outperform the bottom half by a factor of 2 to 1 [8]

Core Insights - Doximity (DOCS) reported first-quarter revenues of $145.9 million, reflecting a 15% year-over-year increase, with an adjusted EBITDA margin of 55% [1][4] - The company is focusing on artificial intelligence as a key component of its strategy, highlighted by the launch of Doximity AI Scribe and the acquisition of Pathway [1][5] Financial Performance - Free cash flow increased by 52% year over year, and net revenue retention remained strong at 118% [4] - Management anticipates an 11% revenue growth for fiscal 2026, despite some caution regarding policy-driven uncertainties [4] AI Initiatives - Doximity AI Scribe has over 10,000 beta testers, with 75% using the tool weekly, which aims to reduce after-hours documentation burdens for physicians [2][9] - The $26 million acquisition of Pathway enhances Doximity's clinical AI capabilities, introducing a proprietary medical corpus that scored 96% on the U.S. medical licensing exam [3][9] Competitive Landscape - Other companies, such as Certara and GE HealthCare, are also developing AI tools to enhance their offerings, with Certara's software revenues rising 22% year over year to $46 million [7] - GE HealthCare has invested significantly in R&D for AI integration across its products, showcasing new AI-enabled diagnostics and planning to launch nearly 200 AI/ML-enabled devices in the next three years [8]

Economic Indicators - US MBA mortgage applications fell by -12.7% in the week ended September 26, with the purchase mortgage sub-index down -1.0% and the refinancing sub-index down -20.6% [1] - The September ISM manufacturing index rose +0.4 to a 7-month high of 49.1, exceeding expectations of 49.0 [6] - The September ADP employment change unexpectedly fell by -32,000, marking the largest decline in 2.5 years, while August was revised lower to -3,000 from +54,000 [5] Market Reactions - Stocks initially moved lower due to the US government shutdown, but later recovered, with the S&P 500 and Nasdaq 100 reaching new all-time highs [2][4] - The dollar index fell to a one-week low, while gold prices climbed to a record high amid risk-off sentiment [2] - Rising corporate earnings expectations are a bullish backdrop for stocks, with over 22% of S&P 500 companies providing guidance for Q3 earnings that are expected to beat analysts' expectations [8] Sector Performance - Pharmaceutical stocks rallied, with AstraZeneca closing up more than +9% and Eli Lilly up more than +8%, driven by hopes from Pfizer's deal with the US government [15] - Chipmakers and AI-infrastructure stocks also saw gains, with Super Micro Computer closing up more than +9% and Micron Technology up more than +8% [16] - Grocery retailers declined after Amazon announced a new private-label food brand, leading to Dollar Tree and Dollar General closing down more than -4% and -3% respectively [22] Upcoming Economic Data - Weekly initial unemployment claims are expected to increase by +7,000 to 225,000, and August factory orders are expected to rise by +1.4% month-over-month [9] - September nonfarm payrolls are anticipated to increase by +51,000, with the unemployment rate expected to remain unchanged at 4.3% [9]

Core Insights - Doximity, Inc. is recognized as a leading healthcare technology stock, utilizing AI-driven tools and strategic acquisitions to enhance its market position [1] - The recent acquisition of Pathway Medical significantly improves Doximity's DoxGPT tool, providing instant access to verified medical data and AI responses [2] - Doximity has introduced Doximity Scribe, an AI tool that automates clinical documentation, thereby reducing administrative workload for clinicians [3] Financial Performance - In the last quarter ending June 30, 2025, Doximity reported a 15% year-over-year revenue increase, reaching $145.9 million, surpassing analyst expectations [4] - The company achieved non-GAAP earnings per share (EPS) of $0.36, indicating strong financial performance [4] - User engagement and product adoption have notably increased, particularly for new AI scribe and workflow tools [4]

Upgrades - Baird upgraded United Rentals (URI) to Outperform from Neutral with a price target of $1,050, up from $888, indicating stabilization in the rental industry after two years of deceleration [2] - Jefferies upgraded Sunrun (RUN) to Buy from Hold with a price target of $21, up from $11, expecting cash generation to materialize in the second half and strong growth through 2026 as U.S. Third-Party Owners gain market share [3] - HSBC upgraded Autodesk (ADSK) to Buy from Hold with a price target of $343, down from $388, noting Autodesk's potential to monetize artificial intelligence and likely margin expansion [4] - Jefferies upgraded Delta Air Lines (DAL) to Buy from Hold with a price target of $70, up from $62, citing a raised Q3 revenue outlook to 2%-4% from 0%-4% as a sign of confidence in topline growth for Q4 and 2026 [5] - Jefferies upgraded Carvana (CVNA) to Buy from Hold with a price target of $475, up from $385, based on consumer survey results and capacity analysis suggesting continued elevated growth [6] Downgrades - Northland double downgraded DraftKings (DKNG) to Underperform from Outperform with a price target of $33, down from $53, due to increasing headwinds from prediction markets [7] - RBC Capital downgraded GE Vernova (GEV) to Sector Perform from Outperform with a price target of $605, down from $631, as current valuations reflect strong demand and productivity improvements [7] - Evercore ISI downgraded Allstate (ALL) to In Line from Outperform with a price target of $233, up from $230, citing over-earning in auto insurance and limited scope for positive estimate revisions [7] - Goldman Sachs downgraded Doximity (DOCS) to Sell from Neutral with a price target of $64, up from $57, indicating the growth profile does not support the current valuation [7] - Goldman Sachs downgraded LivaNova (LIVN) to Neutral from Buy with a price target of $55, down from $56, due to decelerating sales growth and slowing margin expansion [7]